Welcome to the Unity Software fourth quarter 2024 earnings call. My name is Daniel Amir, VP and Head of Investor Relations. Our earnings press release and investor spreadsheet is now available on our ...
UNITY is on track to receive 24-week topline data from its Phase 2b ASPIRE study in diabetic macular edema this quarter, which could provide critical insights for future trials. UBX1325 (foselutoclax) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback